Clearside Biomedical Inc reports results for the quarter ended March 31 - Earnings Summary

• Clearside Biomedical Inc CLSD.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of seven analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -13 cents to -8 cents per share.

• Revenue rose 913% to $2.33 million from a year ago; analysts expected $170.00 thousand.

• Clearside Biomedical Inc's reported EPS for the quarter was a loss of 11 cents​.

• The company reported a quarterly loss of $8.22 million.

• Clearside Biomedical Inc shares had fallen by 2.0% this quarter and lost 5.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 16.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Clearside Biomedical Inc is $5.50

This summary was machine generated from LSEG data May 14 at 09:03 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)